Mayne Pharma acquires rights to fentanyl TDS
ADELAIDE, South Australia — Mayne Pharma acquired the rights to the fentanyl transdermal delivery system, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr from Par Pharmaceutical, which allows the company to now market the product in the United States.
This product was developed by Corium, a specialty pharmaceutical company focused on the development and manufacture of transdermal and transmucosal delivery systems. Fentanyl TDS is a generic equivalent to Duragesic, indicated for the management of pain in opioid-tolerant patients, severe enough to require daily treatment.
Mayne Pharma has assumed Par’s manufacturing and supply agreement with Corium. “We are very pleased to have partnered with Corium on another complex, difficult-to-develop and manufacture product,” said Mayne Pharma’s CEO Scott Richards. “The U.S. transdermal patch market is valued at more than $3.3 billion and is a well-regarded advanced drug delivery system that can better control drug release and can also lead to improved patient convenience and compliance.”
According to IMS Health, the annual market sales for the fentanyl patch were approximately $560 million for the 12 months ending Dec. 31.
“Mayne Pharma’s first marketed patch was Clonidine, indicated for the treatment of hypertension and is one of Mayne Pharma’s top five generic products by sales,” said Richards. “Our alliance with Corium now includes two marketed and one pipeline product that is filed with the U.S. Food and Drug Administration and reinforces one of the key strategic benefits of the Teva Portfolio acquisition to access a pipeline of new product opportunities through leveraging relationships with active pharmaceutical ingredient suppliers and contract development and manufacturing companies.”
No comments found
SoFi takes a look at best-value pharmacy schools
The San Francisco high salary is all well and good, but don't forget to factor in the fact that this is THE MOST EXPENSIVE city in which to live. You cannot compare $ to $ from city to city. Apples and oranges my friend.
Kmart garners top ranking on pharmacy customer satisfaction index
ANN ARBOR, Mich. — Kmart earned the top ranking — a score of 84 out of a possible 100 — in the health and wellness/pharmacy category in the recently released American Customer Satisfaction Index “Retail Report 2016.” Kmart’s ranking rose from a score of 76 the prior year, good for a 10.5% year-over-year increase.
Alberstons placed second on the list with a score of 83, followed by “all others” at 82, Kroger at 81, Target at 79, Rite Aid at 78, and CVS, Walgreens and Walmart all finishing with a score of 76. Of note, Albertsons, Rite Aid, CVS, Walgreens and Walmart all saw significant rises in year-over-year customer satisfaction, with all advancing at least 3%.
Overall, customer satisfaction in this category rose 6.8% year over year to an ACSI score of 78. Customers were especially happy with locations and operating hours of health and personal care stores, scoring an 86 in this category, beating out other retail categories.
The quality of pharmacy services also saw a strong rise in 2016, rising 4% to a score of 84. “According to customers, staff are more courteous and helpful than they were a year ago, and the checkout process, is faster (both up 5% to 83 and 79, respectively),” ACSI noted in its report. “Customers crave more sales and promotions as they still rate the feature at the low end, although there is slight improvement (up 1% to 76).
To compile its statistics, Ann Arbor-based ACSI uses data from interviews with roughly 70,000 customers annually as inputs to an econometric model for analyzing customer satisfaction with more than 300 companies in 43 industries and 10 economic sectors.
For more information about the report, click here.
No comments found